A detailed history of Bryn Mawr Trust CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 82,223 shares of ABBV stock, worth $14.8 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
82,223
Previous 31,992 157.01%
Holding current value
$14.8 Million
Previous $5.49 Million 195.92%
% of portfolio
0.3%
Previous 0.22%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 25, 2024

BUY
$163.84 - $199.33 $8.23 Million - $10 Million
50,231 Added 157.01%
82,223 $16.2 Million
Q2 2024

Aug 08, 2024

SELL
$154.79 - $180.76 $165,160 - $192,870
-1,067 Reduced 3.23%
31,992 $5.49 Million
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $307,493 - $350,360
-1,924 Reduced 5.5%
33,059 $6.02 Million
Q3 2023

Nov 15, 2023

SELL
$133.59 - $154.65 $79,085 - $91,552
-592 Reduced 1.66%
34,983 $5.21 Million
Q2 2023

Aug 11, 2023

BUY
$132.51 - $164.9 $98,189 - $122,190
741 Added 2.13%
35,575 $4.79 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $74,329 - $85,601
-514 Reduced 1.45%
34,834 $5.55 Million
Q4 2022

Feb 10, 2023

SELL
$138.31 - $165.87 $168,461 - $202,029
-1,218 Reduced 3.33%
35,348 $5.71 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $71,533 - $82,044
533 Added 1.48%
36,566 $4.91 Million
Q2 2022

Aug 11, 2022

SELL
$137.62 - $174.96 $267,670 - $340,297
-1,945 Reduced 5.12%
36,033 $5.52 Million
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $29,167 - $36,188
-221 Reduced 0.58%
37,978 $6.16 Million
Q4 2021

Feb 10, 2022

SELL
$107.43 - $135.93 $125,800 - $159,174
-1,171 Reduced 2.97%
38,199 $5.17 Million
Q3 2021

Oct 26, 2021

SELL
$106.4 - $120.78 $47,986 - $54,471
-451 Reduced 1.13%
39,370 $4.25 Million
Q2 2021

Jul 29, 2021

BUY
$105.21 - $117.21 $169,598 - $188,942
1,612 Added 4.22%
39,821 $4.49 Million
Q1 2021

Apr 23, 2021

SELL
$102.3 - $112.62 $104,243 - $114,759
-1,019 Reduced 2.6%
38,209 $4.14 Million
Q4 2020

Feb 11, 2021

SELL
$80.49 - $108.67 $95,863 - $129,425
-1,191 Reduced 2.95%
39,228 $4.2 Million
Q3 2020

Nov 12, 2020

SELL
$85.91 - $100.83 $111,683 - $131,079
-1,300 Reduced 3.12%
40,419 $3.54 Million
Q2 2020

Aug 13, 2020

SELL
$73.37 - $98.18 $52,386 - $70,100
-714 Reduced 1.68%
41,719 $4.1 Million
Q1 2020

May 08, 2020

BUY
$64.5 - $97.79 $213,043 - $323,000
3,303 Added 8.44%
42,433 $3.23 Million
Q4 2019

Feb 11, 2020

SELL
$72.13 - $90.25 $243,222 - $304,323
-3,372 Reduced 7.93%
39,130 $3.47 Million
Q3 2019

Oct 24, 2019

BUY
$62.98 - $75.72 $37,032 - $44,523
588 Added 1.4%
42,502 $3.22 Million
Q2 2019

Aug 15, 2019

SELL
$65.7 - $83.98 $153,343 - $196,009
-2,334 Reduced 5.27%
41,914 $3.05 Million
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $371,506 - $437,244
4,816 Added 12.21%
44,248 $3.57 Million
Q4 2018

Feb 15, 2019

BUY
$77.85 - $96.01 $86,724 - $106,955
1,114 Added 2.91%
39,432 $3.64 Million
Q3 2018

Aug 28, 2019

BUY
$88.91 - $98.84 $3,556 - $3,953
40 Added 0.1%
38,318 $3.62 Million
Q3 2018

Nov 15, 2018

SELL
$88.91 - $98.84 $52,634 - $58,513
-592 Reduced 1.52%
38,278 $3.62 Million
Q2 2018

Aug 28, 2019

BUY
$89.78 - $106.23 $3,591 - $4,249
40 Added 0.1%
38,870 $3.6 Million
Q2 2018

Aug 14, 2018

SELL
$89.78 - $106.23 $22,534 - $26,663
-251 Reduced 0.64%
38,830 $3.6 Million
Q1 2018

Aug 28, 2019

BUY
$92.01 - $123.21 $7,360 - $9,856
80 Added 0.21%
39,081 $3.7 Million
Q1 2018

May 15, 2018

SELL
$92.01 - $123.21 $37,080 - $49,653
-403 Reduced 1.02%
39,001 $3.69 Million
Q4 2017

Aug 28, 2019

BUY
$89.56 - $98.21 $537 - $589
6 Added 0.02%
39,404 $3.81 Million
Q4 2017

Feb 15, 2018

SELL
$89.56 - $98.21 $121,264 - $132,976
-1,354 Reduced 3.32%
39,398 $3.81 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $2.85 Million - $3.64 Million
40,752
40,752 $3.62 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Bryn Mawr Trust CO Portfolio

Follow Bryn Mawr Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bryn Mawr Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Bryn Mawr Trust CO with notifications on news.